Use of convalescent plasma therapy in eight individuals with mild COVID-19

Li, Wen; Hao, Da-Ang; Cheng, Juan; Tong, Xuecheng; Hao, Jungui; Wang, Liping; Li, Chunyang; Dai, Mingjia; Yan, Xuebing

doi:10.1016/j.nmni.2020.100814

Cited by 6 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All patients showed negative RT-PCR result after CPT and this is in accordance with study by Franchini. This result also shows the possibility of convalescent plasma protective effect for people with certain conditions who can not receive the vaccine [30][31][32][33][34][35]. C-Reactive Protein (CRP), as progressivity marker, decreased one day after CPT.…”

Section: Discussionmentioning

confidence: 76%

Convalescent Plasma Effect to Neutralization Antibody and Inflammation Parameter Level in Moderate COVID-19 Patients

Rahardjo¹,

Subroto²,

Adiutama³

et al. 2023

Proceedings of the 1st International Conference for Health Research – BRIN (ICHR 2022)

View full text Add to dashboard Cite

The pandemic of COVID-19 continues with new variants. More than 401 million people in the world infected by COVID-19 and approximately 5.7 million people lost their lives. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has respiratory system as a target. This virus uses a receptor binding domain of SARS-CoV-2 Spike (sRBD) protein to bind ACE-2 receptor and enter human respiratory cells. The antibody to sRBD protein will block the virus. Convalescent plasma from recovered COVID-19 patient contains neutralization antibody which can neutralize sRBD and eliminate the virus. Therefore, this study aims to assess the therapeutic effect of convalescent plasma to neutralization antibody and inflammatory parameter level in moderate COVID-19 patients. This is a one-group pretest-posttest study of nine moderate COVID-19 patients admitted in Unggul Karsa Medika Hospital, Bandung, Indonesia. The study was done from August 1, 2021 to January 1, 2022. The level of neutralization antibody and inflammatory parameter were assessed before and after convalescent plasma therapy in moderate COVID-19 patient. Data analysis performed by SPSS program with p < 0.05 and dependent t-test. Our study shows that convalescent plasma therapy can influence the increase of neutralization antibody (142. 5 AU/mL vs 13.432 AU/mL, p value = 0.011) and the decrease of Interleukin-6 (IL-6) (41.61 pg/mL vs 14.5 pg/mL, p value = 0.008) and C-reactive protein (CRP) level (84.2 mg/L vs 17.4 mg/L, p-value = 0.018) in moderate COVID-19 patient. The patients were also getting better clinically, with the use of oxygen decreasing gradually from non-rebreathing masks to nasal cannula and from nasal cannula to room air after given convalescent plasma therapy. Therefore, we conclude that convalescent plasma therapy has a positive role in increasing neutralization antibody and decreasing inflammatory parameters which are IL-6 and CRP, thus had potential usefulness in therapy for moderate COVID-19 patients.

show abstract

Section: Discussionmentioning

confidence: 76%

Convalescent Plasma Effect to Neutralization Antibody and Inflammation Parameter Level in Moderate COVID-19 Patients

Rahardjo¹,

Subroto²,

Adiutama³

et al. 2023

Proceedings of the 1st International Conference for Health Research – BRIN (ICHR 2022)

View full text Add to dashboard Cite

show abstract

“…Enquanto isso, a plasma convalescente provavelmente aumenta a resposta inflamatória ao SARS-CoV-2 temporariamente em pessoas com imunidade antiviral insuficiente. No entanto, os efeitos do plasma convalescente não são permanentes (Ji et al, 2021).…”

Section: Terapias Celularesunclassified

COVID-19: a historicidade das terapêuticas no primeiro ano da Pandemia

Andolfatto

Zanatta

Ferraz

2022

RSD

View full text Add to dashboard Cite

Objetiva-se conhecer os construtos terapêuticos da COVID-19 em seu primeiro ano de pandemia. Trata-se de uma revisão narrativa da literatura, realizada a partir de pesquisas nas bases Biblioteca Virtual de Saúde, Periódicos Capes, PubMed, Cochrane com os descritores padronizados ‘Therapy’ AND COVID-19, no primeiro ano da pandemia da COVID-19, após a declaração oficial da OMS. Como resultados foram descritos os alvos terapêuticos pesquisados (in vivo, in vitro e in silico) e publicados no primeiro ano dessa crise sanitária. Evidenciou-se que as terapias exploradas se basearam em alvos farmacológicos e não farmacológicos sobre o hospedeiro, sistema imunológico e no vírus. Os principais agentes testados in vitro e in vivo e in silico pertences as classes farmacológicas dos antivirais, antiparasitários, anti-inflamatórios, antibióticos além de anticorpos monoclonais, células-tronco e plasma convalescente. Segundo as publicações, os medicamentos mais citados para tratar a COVID-19 foram a hidroxicloroquina, cloroquina, ivermectina, azitromicina, vitamina D, dexametasona ou outro glicocorticoide. Constatou-se que muitas estratégias terapêuticas contra a COVID-19 foram refutadas, todavia outras estão sendo melhor pesquisadas.

show abstract

A novel HBc-S230 protein chimeric VLPs induced robust immune responses against SARS-CoV-2

Feng,

Chen,

et al. 2024

International Immunopharmacology

View full text Add to dashboard Cite

Use of convalescent plasma therapy in eight individuals with mild COVID-19

Cited by 6 publications

References 17 publications

Convalescent Plasma Effect to Neutralization Antibody and Inflammation Parameter Level in Moderate COVID-19 Patients

Convalescent Plasma Effect to Neutralization Antibody and Inflammation Parameter Level in Moderate COVID-19 Patients

COVID-19: a historicidade das terapêuticas no primeiro ano da Pandemia

A novel HBc-S230 protein chimeric VLPs induced robust immune responses against SARS-CoV-2

Contact Info

Product

Resources

About